PortfoliosLab logoPortfoliosLab logo
IHE vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

IHE vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares U.S. Pharmaceuticals ETF (IHE) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IHE achieves a 6.47% return, which is significantly lower than IDNA's 10.31% return.


IHE

1D
1.16%
1M
1.80%
YTD
6.47%
6M
8.51%
1Y
40.15%
3Y*
17.47%
5Y*
9.98%
10Y*
7.81%

IDNA

1D
0.73%
1M
-2.56%
YTD
10.31%
6M
8.52%
1Y
40.87%
3Y*
6.74%
5Y*
-8.42%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

IHE vs. IDNA - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
IHE
iShares U.S. Pharmaceuticals ETF
6.47%31.69%8.13%1.06%-4.87%13.07%13.66%10.88%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
10.31%17.26%-0.72%-7.63%-42.28%-3.98%54.30%20.83%

Correlation

The correlation between IHE and IDNA is 0.69, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.69

Correlation (3Y)
Calculated over the trailing 3-year period

0.61

Correlation (5Y)
Calculated over the trailing 5-year period

0.60

Correlation (All Time)
Calculated using the full available price history since Jun 14, 2019

0.61

The correlation between IHE and IDNA has been stable across timeframes, ranging from 0.60 to 0.69 - a consistent structural relationship.

IHE vs. IDNA - Sectors Allocation Comparison


Sectors
IHE
IDNA

Healthcare

100.0%
97.8%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

-

Industrials

-

0.4%

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

IHE
100.0%
IDNA
97.8%

Basic Materials

IHE

-

IDNA

-

Communication Services

IHE

-

IDNA

-

Consumer Cyclical

IHE

-

IDNA

-

Consumer Defensive

IHE

-

IDNA

-

Energy

IHE

-

IDNA

-

Financial Services

IHE

-

IDNA

-

Industrials

IHE

-

IDNA
0.4%

Real Estate

IHE

-

IDNA

-

Technology

IHE

-

IDNA

-

Utilities

IHE

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IHE vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IHE
IHE Risk / Return Rank: 7474
Overall Rank
IHE Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
IHE Sortino Ratio Rank: 7575
Sortino Ratio Rank
IHE Omega Ratio Rank: 6565
Omega Ratio Rank
IHE Calmar Ratio Rank: 8585
Calmar Ratio Rank
IHE Martin Ratio Rank: 7575
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 5555
Overall Rank
IDNA Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 4949
Sortino Ratio Rank
IDNA Omega Ratio Rank: 4242
Omega Ratio Rank
IDNA Calmar Ratio Rank: 7676
Calmar Ratio Rank
IDNA Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IHE vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares U.S. Pharmaceuticals ETF (IHE) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IHEIDNADifference
Sharpe ratioReturn per unit of total volatility

+0.68

Sortino ratioReturn per unit of downside risk

+0.99

Omega ratioGain probability vs. loss probability

1.40

1.27

+0.13

Calmar ratioReturn relative to maximum drawdown

4.76

3.85

+0.91

Martin ratioReturn relative to average drawdown

14.35

10.98

+3.37

IHE vs. IDNA - Sharpe Ratio Comparison

The current IHE Sharpe Ratio is 2.36, which is higher than the IDNA Sharpe Ratio of 1.68. The chart below compares the historical Sharpe Ratios of IHE and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


IHEIDNADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.36

1.68

+0.68

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.62

-0.30

+0.92

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.43

Sharpe Ratio (All Time)

Calculated using the full available price history

0.51

0.10

+0.40

Drawdowns

IHE vs. IDNA - Drawdown Comparison

The maximum IHE drawdown since its inception was -38.20%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for IHE and IDNA.


Loading charts...

Drawdown Indicators


IHEIDNADifference

Max Drawdown

Largest peak-to-trough decline

-38.20%

-68.26%

+30.06%

Max Drawdown (1Y)

Largest decline over 1 year

-8.47%

-10.66%

+2.19%

Max Drawdown (3Y)

Largest decline over 3 years

-15.92%

-29.73%

+13.81%

Max Drawdown (5Y)

Largest decline over 5 years

-16.03%

-68.26%

+52.23%

Max Drawdown (10Y)

Largest decline over 10 years

-29.59%

Current Drawdown

Current decline from peak

-2.80%

-45.61%

+42.81%

Average Drawdown

Average peak-to-trough decline

-7.92%

-36.24%

+28.32%

Ulcer Index

Depth and duration of drawdowns from previous peaks

2.81%

3.73%

-0.92%

Volatility

IHE vs. IDNA - Volatility Comparison

The current volatility for iShares U.S. Pharmaceuticals ETF (IHE) is 5.53%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 7.18%. This indicates that IHE experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IHEIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

5.53%

7.18%

-1.65%

Volatility (6M)

Calculated over the trailing 6-month period

12.48%

17.98%

-5.50%

Volatility (1Y)

Calculated over the trailing 1-year period

17.07%

24.48%

-7.41%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

16.24%

28.42%

-12.18%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

18.05%

29.53%

-11.48%

IHE vs. IDNA - Expense Ratio Comparison

IHE has a 0.42% expense ratio, which is lower than IDNA's 0.47% expense ratio.


Dividends

IHE vs. IDNA - Dividend Comparison

IHE's dividend yield for the trailing twelve months is around 1.65%, more than IDNA's 1.07% yield.


PositionTTM20252024202320222021202020192018201720162015
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.07%1.18%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%0.00%0.00%
IHE
iShares U.S. Pharmaceuticals ETF
1.65%1.76%1.73%1.39%2.01%1.49%1.19%1.40%1.25%1.36%0.92%1.93%

Frequently Asked Questions


IHE and IDNA have a correlation of 0.69, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IDNA has higher volatility (7.18%) compared to IHE (5.53%). In terms of maximum drawdown, IHE dropped -38.20% vs IDNA's -68.26%.

On 5-year performance, IHE leads with 9.98% vs -8.42% for IDNA. On fees, IHE is cheaper at 0.42% per year. On volatility, IHE has been the lower-risk option at 5.53%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, IHE has performed better with a 9.98% return vs -8.42%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IHE is cheaper with a 0.42% expense ratio, compared with 0.47% for IDNA.

IHE has the higher dividend yield at 1.65%, compared with 1.07% for IDNA.

IHE tracks Dow Jones U.S. Select Pharmaceuticals Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. Their fees differ too: 0.42% for IHE and 0.47% for IDNA.

IHE currently has the higher Sharpe Ratio (2.36 vs 1.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IHE and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer